In ASX News, Exopharm

Funds will be used to accelerate the commercialisation of the company’s technology platforms and products − using exosomes to deliver a new class of transformative medicines with the aim of generating revenue from multiple partnership deals

Canary Capital acted as lead manager and Alto Capital as a broker to the issue

Recommended Posts